Navigation Links
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
Date:5/14/2009

FREMONT, Calif., May 14 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "siRNA Therapeutics for Prevention of Ocular and Inner Ear Sensory Cells Death," at the DxRx Summit: Nucleic Acid Diagnostics & Therapeutics. The event was held May 12-13, 2009 in Boston, MA.

Dr. Feinstein presented data demonstrating that synthetic, chemically-modified 19-bp siRNAs, including PF 04523655 currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD), enter cells in the retina of the eye and exert their therapeutic effects while avoiding non-specific activation of the toll-like receptor 3 (TLR3) - the effect reported for other synthetic siRNAs. Similar data for QPI-1007, Quark's proprietary siRNA composition, were also reported. QPI-1007 was demonstrated to confer effective ocular neuroprotection and is currently in late-stage IND-enabling studies.

In addition to studies in the eye, Dr. Feinstein also reported results demonstrating effective delivery of synthetic siRNAs to the inner ear, which resulted in protection of hearing epithelium from ototoxic and noise-induced damage. These studies were performed in collaboration with Prof. Jayakrishna Ambati, University of Kentucky College of Medicine, Lexington, KY; Prof. Ann Logan, University of Birmingham, UK; Prof. Adriana Di Polo, University of Montreal; and Prof. Richard Salvi, SUNY University at Buffalo.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "Results from the studies presented at DxRx demonstrate our successful track record in discovering and advancing industry-leading siRNA product candidates. Our strong position in the RNAi landscape has been validated by our ability to secure co-development agreements with major pharmaceutical partners, including Pfizer, to advance our siRNA product candidates further towards commercialization."

Dr. Feinstein added, "Our synthetic, chemically modified siRNA product candidates have been designed to elicit pharmacologic effects through target gene-knock down while avoiding potentially harmful off-target effects reported for other synthetic siRNAs. These results support our capabilities to discover and develop siRNA product candidates with greater specificity and reduced side effects."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-04523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-04523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.       The Ruth Group (investors / media)
    Juliana Friedmann                 Sara Ephraim Pellegrino / Janine McCargo
    +972 89 30 5111                   (646) 536-7002 / 7033
    jfriedman@quarkpharma.com         spellegrino@theruthgroup.com
                                      jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
2. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
5. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
8. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
9. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
11. Vion Pharmaceuticals Reports 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... ... feel-good lyric music video in Final Cut Pro X with ProLyric from Pixel Film Studios. ... lyrics to any song. ProLyric flies in the text for each section and it hovers ... modularly for optimal control. ProLyric makes editing any music video or text-based production easier than ...
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version ... It differs significantly from the American Health Care Act, which the House passed in ... House will have to take up the Senate version as-is, if it passes. , ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/25/2017)... New Orleans (PRWEB) , ... June 25, 2017 , ... ... ARM Meeting in New Orleans. This is a new, greatly improved version of ... of Information Act (FOIA) requests by Fred Trotter and subsequently called the the “Doctor ...
(Date:6/25/2017)... ... , ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, ... ready is easy with laser hair removal. , The process of summer waxing and ... when all you want to do is get out, dive in and cool off. There ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... 19, 2017  Researchers from DRUGSCAN ® and ... host a live, complimentary webinar titled, "Untangling methods to ... the real world" on Wednesday June 28, 2017 from ... This webinar will feature interviews with recreational and dependent ... manipulation techniques abusers use to prepare opioid tablets for ...
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
Breaking Medicine Technology: